Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial

BACKGROUND: Telbivudine has been suggested to induce hepatitis B surface antigen (HBsAg) decline to the similar degree as pegylated interferon. We aimed to investigate whether telbivudine could further decrease HBsAg titer in patients who maintain undetectable serum hepatitis B virus (HBV) DNA after...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMC Gastroenterol
Autori principali: An, Jihyun, Lim, Young-Suk, Kim, Gi-Ae, Han, Seong-bong, Jeong, Wonhee, Lee, Danbi, Shim, Ju Hyun, Lee, Han Chu, Lee, Yung Sang
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2017
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5248511/
https://ncbi.nlm.nih.gov/pubmed/28103819
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12876-017-0572-2
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi